Gergely Udvarhelyi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Gergely Udvarhelyi has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- László Majoros
Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
3 shared publications - Renátó Kovács
Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
3 shared publications - Zoltán Tóth
Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
3 shared publications - Csaba Kósa
Department of Surgery, Clinical Centre, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
2 shared publications - Dávid Balázsi
Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Nagyerdei krt. 98, 4032 Debrecen, Hungary
2 shared publications - Jacques F. Meis
Department of Medical Microbiology, Radboud University Medical Center, 6525 GA Nijmegen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 24 July 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (8) , 552
In Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade of Candida (Candidozyma) auris
Objectives: The aim of our study was to investigate the in vitro activity and in vivo efficacy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris isolates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs, according to CLSI M27-Ed4, and killing activities were determined in RPMI-1640. In the survival and fungal tissue burden experiments (heart, kidney and brain), neutropenic mice were infected intravenously (1 × 107 CFU/mouse). Treatment was initiated 24 h post-infection with intraperitoneal dosing of 20 mg/kg of rezafungin on days 1, 3 and 6 or once-daily dosing for 6 days with 3 mg/kg of caspofungin, 5 mg/kg of micafungin or 5 mg/kg of anidulafungin. Results: MIC ranges of rezafungin, anidulafungin, caspofungin, and micafungin were 0.06–0.25, ≤0.03–0.12, 0.12–0.5 and ≤0.03–0.12 mg/L, respectively. Growth in RPMI-1640 showed pseudohypha in all five isolates both at 30 °C and 37 °C, but hyphae were never observed. In contrast, echinocandin-treated yeasts at 37 °C showed small and large aggregates of blastoconidia at both 0.25 and 16 mg/L echinocandin concentrations. The four echinocandins at ≥1 mg/L were fungicidal only against isolate MRL40. All echinocandin regimens improved the survival in mice infected with isolates MRL40 and IFRC4050 (p-values were ≤0.0002 and 0.0006, respectively), but only rezafungin was effective against isolate TMML617 (p = 0.0049). All four echinocandins induced more than 4 log mean CFU/gram decreases in the kidneys and hearts of mice infected with isolate MRL40 (p < 0.001 for all echinocandins). Rezafungin and caspofungin significantly decreased the fungal kidney and heart burdens in mice infected with isolate TMML617. Against IFRC4050, rezafungin, anidulafungin and caspofungin significantly decreased the fungal burdens in the kidneys (p < 0.05) and hearts (p < 0.05–0.01). The fungal brain tissue burdens were always higher than 105 CFU/gram. Histopathology showed large aggregates of pseudohyphae in the hearts, kidneys and brains in control mice. In echinocandin-treated mice, only blastoconidia were observed. Conclusions: In vitro activity and in vivo efficacy of the four echinocandins against the fifth clade of C. auris was echinocandin- and isolate-specific. Pseudohyphae production was common in controls, but not in echinocandin-treated mice. Rezafungin activity was comparable to or better than the three previously approved echinocandins.
- 24 July 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (8) , 552
Open AccessIn Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade of Candida (Candidozyma) auris
Objectives: The aim of our study was to investigate the in vitro activity and in vivo efficacy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris isolates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs, according to CLSI M27-Ed4, and killing activities were determined in RPMI-1640. In the survival and fungal tissue burden experiments (heart, kidney and brain), neutropenic mice were infected intravenously (1 × 107 CFU/mouse). Treatment was initiated 24 h post-infection with intraperitoneal dosing of 20 mg/kg of rezafungin on days 1, 3 and 6 or once-daily dosing for 6 days with 3 mg/kg of caspofungin, 5 mg/kg of micafungin or 5 mg/kg of anidulafungin. Results: MIC ranges of rezafungin, anidulafungin, caspofungin, and micafungin were 0.06–0.25, ≤0.03–0.12, 0.12–0.5 and ≤0.03–0.12 mg/L, respectively. Growth in RPMI-1640 showed pseudohypha in all five isolates both at 30 °C and 37 °C, but hyphae were never observed. In contrast, echinocandin-treated yeasts at 37 °C showed small and large aggregates of blastoconidia at both 0.25 and 16 mg/L echinocandin concentrations. The four echinocandins at ≥1 mg/L were fungicidal only against isolate MRL40. All echinocandin regimens improved the survival in mice infected with isolates MRL40 and IFRC4050 (p-values were ≤0.0002 and 0.0006, respectively), but only rezafungin was effective against isolate TMML617 (p = 0.0049). All four echinocandins induced more than 4 log mean CFU/gram decreases in the kidneys and hearts of mice infected with isolate MRL40 (p < 0.001 for all echinocandins). Rezafungin and caspofungin significantly decreased the fungal kidney and heart burdens in mice infected with isolate TMML617. Against IFRC4050, rezafungin, anidulafungin and caspofungin significantly decreased the fungal burdens in the kidneys (p < 0.05) and hearts (p < 0.05–0.01). The fungal brain tissue burdens were always higher than 105 CFU/gram. Histopathology showed large aggregates of pseudohyphae in the hearts, kidneys and brains in control mice. In echinocandin-treated mice, only blastoconidia were observed. Conclusions: In vitro activity and in vivo efficacy of the four echinocandins against the fifth clade of C. auris was echinocandin- and isolate-specific. Pseudohyphae production was common in controls, but not in echinocandin-treated mice. Rezafungin activity was comparable to or better than the three previously approved echinocandins.
- Open Access
- 8 May 2026
- Published by MDPI AG in Preprints.org
In Vitro Activity and In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin and Micafungin Against the Fifth Clade of Candida (Candidozyma) auris
Objectives: The aim of our study was to investigate the in vitro activity and in vivo effica-cy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris iso-lates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs and killing activities were determined in RPMI-1640. In the survival and fungal tissue burden experiments (heart, kidney and brain), neutro-penic mice were infected intravenously (107 CFU/mouse). Treatment was initiated 24 hours post-infection with intraperitoneal dosing of 20 mg/kg of rezafungin on days 1, 3 and 6 or once-daily dosing for 6 days with 3 mg/kg of caspofungin, 5 mg/kg of micafungin or 5 mg/kg of anidulafungin. Results: MIC ranges of rezafungin, anidulafungin, caspofungin, and micafungin were 0.06-0.25, ≤0.03-0.12, 0.12-0.5 and ≤0.03-0.12 mg/L, respectively. The four echinocandins at ≥1 mg/L were fungicidal only against isolate MRL40. All echinocandin regimens im-proved the survival in mice infected with isolates MRL40 and IFRC4050 (P-values were ≤0.0002 and 0.0006, respectively), but only rezafungin was effective against isolate TML617 (P=0.0049). All four echinocandins induced more than 3 logs mean CFU/gram decreases in the kidneys and hearts of mice infected with the three isolates compared to control mice, some of which were not statistically significant. Fungal growth, regardless of the isolate tested, was poorly inhibited by echinocandins in the brain. Histopathology showed large aggregates of pseudohyphae in the hearts, kidneys and brains in control mice. In echinocandin treated mice only blastoconidia were found. Conclusions: In vitro activity and in vivo efficacy of the four echinocandins against the fifth clade of C. auris was echinocandin- and isolate-specific. Pseudohyphal production was common in controls, but not in echinocandin treated mice. Rezafungin activity was comparable to or better than the three previously approved echinocandins.
- 8 May 2026
- Published by MDPI AG in Preprints.org
Open AccessIn Vitro Activity and In Vivo Efficacy of Rezafungin, Anidulafungin, Caspofungin and Micafungin Against the Fifth Clade of Candida (Candidozyma) auris
Objectives: The aim of our study was to investigate the in vitro activity and in vivo effica-cy of rezafungin, anidulafungin, caspofungin and micafungin against Candida auris iso-lates belonging to clade V. Methods: Five clinical isolates were evaluated (IFRC2087, IFRC4050, MRL40, TMML616 and TMML617). Echinocandin MICs and killing activities were determined in RPMI-1640. In the survival and fungal tissue burden experiments (heart, kidney and brain), neutro-penic mice were infected intravenously (107 CFU/mouse). Treatment was initiated 24 hours post-infection with intraperitoneal dosing of 20 mg/kg of rezafungin on days 1, 3 and 6 or once-daily dosing for 6 days with 3 mg/kg of caspofungin, 5 mg/kg of micafungin or 5 mg/kg of anidulafungin. Results: MIC ranges of rezafungin, anidulafungin, caspofungin, and micafungin were 0.06-0.25, ≤0.03-0.12, 0.12-0.5 and ≤0.03-0.12 mg/L, respectively. The four echinocandins at ≥1 mg/L were fungicidal only against isolate MRL40. All echinocandin regimens im-proved the survival in mice infected with isolates MRL40 and IFRC4050 (P-values were ≤0.0002 and 0.0006, respectively), but only rezafungin was effective against isolate TML617 (P=0.0049). All four echinocandins induced more than 3 logs mean CFU/gram decreases in the kidneys and hearts of mice infected with the three isolates compared to control mice, some of which were not statistically significant. Fungal growth, regardless of the isolate tested, was poorly inhibited by echinocandins in the brain. Histopathology showed large aggregates of pseudohyphae in the hearts, kidneys and brains in control mice. In echinocandin treated mice only blastoconidia were found. Conclusions: In vitro activity and in vivo efficacy of the four echinocandins against the fifth clade of C. auris was echinocandin- and isolate-specific. Pseudohyphal production was common in controls, but not in echinocandin treated mice. Rezafungin activity was comparable to or better than the three previously approved echinocandins.
- Open Access
- 29 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1365
In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades
Candida auris is a multidrug-resistant pathogen against which echinocandins are the drug of choice. However, information on how the chitin synthase inhibitor nikkomycin Z influences the killing activities of echinocandins against C. auris is currently lacking. We determined the killing activities of anidulafungin and micafungin (0.25, 1, 8, 16 and 32 mg/L each) with and without nikkomycin Z (8 mg/L) against 15 isolates representing four C. auris clades (South Asian n = 5; East Asian n = 3; South African n = 3; South American n = 4, two of which were of environmental origin). Two and one isolates from the South Asian clade harbored mutations in the hot-spot 1 (S639Y and S639P) and 2 (R1354H) regions of the FKS1 gene, respectively. The anidulafungin, micafungin and nikkomycin Z MIC ranges were 0.015-4, 0.03-4 and 2->16 mg/L, respectively. Anidulafungin and micafungin alone exerted weak fungistatic activity against wild-type isolates and the isolate with a mutation in the hot-spot 2 region of FKS1 but was ineffective against the isolates with a mutation in the hot-spot 1 region. The nikkomycin Z killing curves were always similar to their respective controls. Twenty-two of sixty (36.7%) anidulafungin plus nikkomycin Z and twenty-four of sixty (40%) micafungin plus nikkomycin Z combinations produced at least 100-fold decreases in the CFUs (synergy), with a 41.7% and 20% fungicidal effect, respectively, against wild-type isolates. Antagonism was never observed. Similar results were found with the isolate with a mutation in hot-spot 2 of FKS1, but the combinations were ineffective against the two isolates with prominent mutations in hot-spot 1 of FKS1. The simultaneous inhibition of β-1,3 glucan and chitin synthases in wild-type C. auris isolates produced significantly greater killing rates than either drug alone. Further studies are warranted to verify the clinical efficacy of echinocandin plus nikkomycin Z combinations against echinocandin susceptible C. auris isolates.
- 29 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1365
Open AccessIn Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades
Candida auris is a multidrug-resistant pathogen against which echinocandins are the drug of choice. However, information on how the chitin synthase inhibitor nikkomycin Z influences the killing activities of echinocandins against C. auris is currently lacking. We determined the killing activities of anidulafungin and micafungin (0.25, 1, 8, 16 and 32 mg/L each) with and without nikkomycin Z (8 mg/L) against 15 isolates representing four C. auris clades (South Asian n = 5; East Asian n = 3; South African n = 3; South American n = 4, two of which were of environmental origin). Two and one isolates from the South Asian clade harbored mutations in the hot-spot 1 (S639Y and S639P) and 2 (R1354H) regions of the FKS1 gene, respectively. The anidulafungin, micafungin and nikkomycin Z MIC ranges were 0.015-4, 0.03-4 and 2->16 mg/L, respectively. Anidulafungin and micafungin alone exerted weak fungistatic activity against wild-type isolates and the isolate with a mutation in the hot-spot 2 region of FKS1 but was ineffective against the isolates with a mutation in the hot-spot 1 region. The nikkomycin Z killing curves were always similar to their respective controls. Twenty-two of sixty (36.7%) anidulafungin plus nikkomycin Z and twenty-four of sixty (40%) micafungin plus nikkomycin Z combinations produced at least 100-fold decreases in the CFUs (synergy), with a 41.7% and 20% fungicidal effect, respectively, against wild-type isolates. Antagonism was never observed. Similar results were found with the isolate with a mutation in hot-spot 2 of FKS1, but the combinations were ineffective against the two isolates with prominent mutations in hot-spot 1 of FKS1. The simultaneous inhibition of β-1,3 glucan and chitin synthases in wild-type C. auris isolates produced significantly greater killing rates than either drug alone. Further studies are warranted to verify the clinical efficacy of echinocandin plus nikkomycin Z combinations against echinocandin susceptible C. auris isolates.